Statins as potential treatment for cholesterol gallstones: An attempt to understand the underlying mechanism of actions

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 17, 2011, Pages 2673-2681

  Ahmed, Mohamed H ^a   Hamad, Mahir A ^a   Routh, Charlotte ^a   Connolly, Vincent ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesterol gallstones; CVD; Obesity; Statins

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ESTROGEN; EZETIMIBE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ACUTE CORONARY SYNDROME; AGING; ARTERIAL WALL THICKNESS; BARIATRIC SURGERY; BILE ACID SYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ARTERY INTIMA MEDIA THICKNESS; CHOLECYSTECTOMY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL STONE; COMPARATIVE STUDY; CROHN DISEASE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENTEROHEPATIC CIRCULATION; EXPERIMENTAL ANIMAL; GALLSTONE DISSOLUTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPID DIET; LIVER CIRRHOSIS; MEDLINE; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SHORT COURSE THERAPY; TREATMENT DURATION; WAIST CIRCUMFERENCE;

ANIMALS; CHOLESTEROL; GALLSTONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; NAPHTHALENES;

EID: 81255134966     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.629995     Document Type: Review

References (71)

1. Petroni ML, Jazrawi RP, Pazzi P, et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol 2000;12:695-700
2. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005;7:132-40
3. Heaton KW. Review article: epidemiology of gall-bladder disease - role of intestinal transit. Aliment Pharmacol Ther 2000;14(Suppl 2):9-13
4. Heaton KW. Cholesterol-rich gallstones. Mol Aspects Med 1987;9:89-96
5. Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am 1991;20:1-19
6. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004;80:38-44
7. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut 2006;55:708-14
8. Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998;128:417-25
9. Festi D, Dormi A, Capodicasa S, et al. Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol 2008;14:5282-9
10. Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008;14:778-82
11. Wang HH, Portincasa P, Afdhal NH, Wang DQ. Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am 2010;39:185-viii
12. Wang HH, Portincasa P, Wang DQ. Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci 2008;13:401-23
13. Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006;20:981-96
14. Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology 2010;2:508-16
15. Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC, et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol 2005;100:827-30
16. Mendez-Sanchez N, Zamora-Valdes D, Flores-Rangel JA, et al. Gallstones are associated with carotid atherosclerosis. Liver Int 2008;28:402-6
17. Bortnichak EA, Freeman DH Jr, Ostfeld AM, et al. The association between cholesterol cholelithiasis and coronary heart disease in Framingham, Massachusetts. Am J Epidemiol 1985;121:19-30
18. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
19. Portincasa P, Moschetta A, Petruzzelli M, et al. Gallstone disease: symptoms and diagnosis of gallbladder stones. Best Pract Res Clin Gastroenterol 2006;20:1017-29
20. Ahmed MH. Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials. World J Gastroenterol 2010;16:1555-7
21. Marschall HU, Einarsson C. Gallstone disease. J Intern Med 2007;261:529-42
22. Ahmed MH, Osman MM, Alokail MS. Statins and breast cancer: a smoking gun or guilt by association? Expert Opin Drug Saf 2006;5:599-601
23. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60
24. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095-100
25. Pasterkamp G, van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther 2010;8:1235-7
26. Gurll N, DenBesten L. Animal models of human cholesterol gallstone disease: a review. Lab Anim Sci 1978;28:428-32
27. Brenneman DE, Connor WE, Forker EL, DenBesten L. The formation of abnormal bile and cholesterol gallstones from dietary cholesterol in the prairie dog. J Clin Invest 1972;51:1495-503
28. Holzbach RT. Animal models of cholesterol gallstone disease. Hepatology 1984;4:191-198S
29. Saunders KD, Cates JA, Abedin MZ, et al. Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg 1991;2:149-54
30. Abedin MZ, Narins SC, Park EH, et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs. Dig Dis Sci 2002;47:2192-210
31. Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes Surg 2003;13:865-8
32. Tazuma S, Hatsushika S, Aihara N, et al. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion 1992;51:179-84
33. Saunders KD, Cates JA, Abedin MZ, Roslyn JJ. Lovastatin and gallstone dissolution: a preliminary study. Surgery 1993;113:28-35
34. Erichsen R, Froslev T, Lash TL, et al. Long-term statin use and the risk of gallstone disease: a population-based case-control study. Am J Epidemiol 2011;173:162-70
35. Bodmer M, Brauchli YB, Krahenbuhl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302:2001-7
36. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009;136:1593-600
37. Merzon E, Weiss NS, Lustman AJ, et al. Statin administration and risk of cholecystectomy: a population-based case-control study. Expert Opin Drug Saf 2010;9:539-43
38. Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001;46:540-4
39. Sackmann M, Koelbl R, Pauletzki J, et al. Simvastatin added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shock wave therapy. Z Gastroenterol 1995;33:585-9
40. Duane WC, Hunninghake DB, Freeman ML. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988;8:1147-50
41. Logan GM, Duane WC. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology 1990;98:1572-6
42. Nitsche R, Schlage J, Ramin V, et al. Influence of the HMG-CoA-reductase inhibitor lovastatin on cholesterol saturation index and nucleation time of duodenal bile. Z Gastroenterol 1991;29:242-5
43. Duane WC. Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid Xomposition in healthy male subjects. J Lipid Res 1994;35:501-9
44. Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 1998;26:287-91
45. Hillebrant CG, Nyberg B, Gustafsson U, et al. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism. Eur J Clin Invest 2002;32:528-34
46. Hillebrant CG, Axelson M, Bjorkhem I, et al. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest 1998;28:324-8
47. Smith JL, Roach PD, Wittenberg LN, et al. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 2000;15:871-9
48. Chapman BA, Burt MJ, Chisholm RJ, et al. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor. Dig Dis Sci 1998;43:349-53
49. Vaishnavi C, Singh S, Kochhar R, et al. C-reactive protein in patients with gallbladder and biliary tract diseases. Trop Gastroenterol 2004;25:73-5
50. Maurer KJ, Carey MC, Fox JG. Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology 2009;136:425-40
51. Ahmed MH, Byrne CD. Metabolic syndrome, diabetes & CHD risk. In: Packard CJ, editor. The year in lipid disorders. Clinical Publishing; Oxford: 2007. p. 3-26
52. Ahmed MH, Byrne CD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 2007;12:740-7
53. Ahmed MH, Abu EO, Byrne CD. Non-alcoholic fatty liver disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes 2010;3:129-37
54. Caroli-Bosc FX, Le Gall P, Pugliese P, et al. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 2001;46:540-4
55. Raedsch R, Plachky J, Wolf N, Simonis G. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment. Eur J Drug Metab Pharmacokinet 1995;20:113-18
56. Wilson IR, Hurrell MA, Pattinson NR, Chapman BA. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics. J Gastroenterol Hepatol 1994;9:447-51
57. Jonkers IJ, Smelt AH, Princen HM, et al. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J Nutr 2006;136:987-91
58. Jonkers IJ, Smelt AH, Ledeboer M, et al. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 2003;52:109-15
59. Mendez-Sanchez N, Gonzalez V, Aguayo P, et al. Fish oil (n-3) polyunsaturated fatty acids beneficially affect biliary cholesterol nucleation time in obese women losing weight. J Nutr 2001;131:2300-3
60. Magnuson TH, Lillemoe KD, High RC, Pitt HA. Dietary fish oil inhibits cholesterol monohydrate crystal nucleation and gallstone formation in the prairie dog. Surgery 1995;118:517-23
61. Berr F, Holl J, Jungst D, et al. Dietary N-3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease. Hepatology 1992;16:960-7
62. Mathur A, Walker JJ, Al-Azzawi HH, et al. Ezetimibe ameliorates cholecystosteatosis. Surgery 2007;142:228-33
63. Valasek MA, Repa JJ, Quan G, et al. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008;295:G813-22
64. Zuniga S, Molina H, Azocar L, et al. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008;28:935-47
65. Wang HH, Portincasa P, Mendez-Sanchez N, et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008;134:2101-10
66. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
67. Holland RE, Rahman K, Morris AI, et al. Effects of niacin on biliary lipid output in the rat. Biochem Pharmacol 1993;45:43-9
68. Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(Suppl 1):S53-8
69. Gustafsson BE, Angelin B, Einarsson K, Gustafsson JA. Influence of cholestyramine on synthesis of cholesterol and bile acids in germfree rats. J Lipid Res 1978;19:972-7
70. Carrella M, Ericsson S, Del Piano C, et al. Effect of cholestyramine treatment on biliary lipid secretion rates in normolipidaemic men. J Intern Med 1991;229:241-6
71. Bertolotti M, Abate N, Loria P, et al. Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo. Hepatology 1991;14:830-7